San Donato Hospital
Die CAR-T-Zell-Therapie in Italien kostet für den gesamten klinischen Pfad üblicherweise zwischen $350,000 und $500,000. Der endgültige Preis hängt vom verwendeten Medikament, der Dauer der stationären Überwachung und der Behandlung möglicher Nebenwirkungen ab. Patienten sparen etwa 18% im Vergleich zu Deutschland, wo die Behandlung im Durchschnitt $425,000 kostet. Die meisten italienischen Protokolle umfassen die Zellgewinnung, die Herstellung im Labor und eine fachärztliche stationäre Betreuung in Mailand oder Rom.
Expertenmeinung von Bookimed: Die Wahl eines forschungsstarken Zentrums wie das San Raffaele in Mailand ermöglicht den Zugang zu weltweit anerkannten Hämatologen wie Prof. Fabio Ciceri. Diese Klinik zählt laut Newsweek zu den besten Krankenhäusern der Welt und bietet die CAR-T-Zell-Therapie ab circa 120.550 € an. Während dieser Basispreis den wesentlichen Eingriff abdeckt, garantiert der Aufenthalt in einer IRCCS-akkreditierten Einrichtung höchste Standards für komplexe genetische und immunologische Fälle.
Warum Italien für die CAR-T-Zelltherapie wählen?
Zugang zu fortschrittlichen CAR-T-Zelltherapie-Lösungen in vertrauenswürdigen Kliniken .
| Italien | Türkei | Österreich | |
| CAR-T-Zelltherapie | von $350,000 | von $150,000 | von $350,000 |
Bookimed erhebt keine zusätzlichen Gebühren für CAR-T-Zelltherapie-Preise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihr CAR-T-Zelltherapie bei Ihrer Ankunft.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards für CAR-T-Zelltherapie einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu versorgen.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer CAR-T-Zelltherapie-Reise nie allein.
Tag 1
Tag 2 – Tag 3
Tag 4
Tag 5 – Tag 12
Tag 13
Tag 14 – Tag 20
Woche 3 – Woche 4
Ab Woche 5
Bitte beachten Sie, dass jeder Fall individuell ist. Dieser Zeitplan kann je nach Ihrem persönlichen Gesundheitszustand und den Besonderheiten Ihres Behandlungsplans variieren.
Studienleiter (Principal Investigator) in klinischen Studien zur CAR-T-Zelltherapie – Professor Ciceri leitet die Abteilung für Hämatologie und Knochenmarktransplantation des San Raffaele Krankenhauses.
CAR T-cell therapy is available in Italy as a standard treatment for relapsed or refractory hematological malignancies like lymphoma and leukemia. The Italian Medicines Agency (AIFA) regulates these therapies, which are primarily delivered through specialized IRCCS-accredited research hospitals and university clinics.
Bookimed Expert Insight: While northern Italy clinics like San Raffaele handle the highest patient volumes, data shows a trend where centers in southern Italy, such as Cardarelli Hospital in Naples, may offer faster navigation through administrative bureaucracy. Patients should compare wait times across regions, as northern hubs often face higher demand despite having more facilities.
Patient Consensus: Seeking treatment early is vital as intensive prior chemotherapy can impact eligibility. Patients frequently note that the pre-approval process is rigorous and may require several months of waiting.
Eligibility for CAR T-cell therapy in Italy requires patients to have relapsed or refractory hematological cancers. Candidates must fail at least two prior lines of systemic therapy. The Italian Medicines Agency governs access through specialized hub centers like San Raffaele in Milan.
Bookimed Expert Insight: While Italy follows European Medicines Agency standards, the Italian Medicines Agency often sets stricter age caps. Professor Fabio Ciceri at San Raffaele leads critical cell therapy trials that may offer earlier access. Patients often wait 3–6 months for manufacturing, so early referral to a hub is vital.
Patient Consensus: Many find the approval process rigorous and sometimes describe it as a lottery. Moving quickly between treatment lines is essential to remain healthy enough for the manufacturing period.
Italy's national healthcare system (Servizio Sanitario Nazionale) fully covers CAR T-cell therapy for eligible patients. The Italian Medicines Agency (AIFA) grants these treatments innovation status, meaning public funding applies at authorized hematology centers for specific relapsed or refractory B-cell malignancies and multiple myeloma.
Bookimed Expert Insight: While Italy offers full public coverage, the concentration of authorized centers in Lombardy and Lazio creates significant geographic disparities. Patients often choose San Raffaele because it combines IRCCS research accreditation with massive clinical volume, serving 300,000 patients annually. This helps navigate the complex AIFA drug registry requirements faster than smaller regional hospitals.
Patient Consensus: Patients emphasize that while treatment is free for citizens, the approval process can take 6 months. Many suggest starting the eligibility verification early at AIFA-approved centers to manage the 3-to-12 month waiting periods effectively.
Italy is a global leader in CAR T-cell therapy, with San Raffaele in Milan and Bambino Gesù Children Hospital in Rome serving as primary hubs. These AIFA-authorized centers specialize in cell and gene therapy clinical trials for adult hematology and pediatric neuroblastoma.
Bookimed Expert Insight: Data shows San Raffaele maintains a unique position by integrating world-first stem cell breakthroughs with CAR-T delivery. While many centers offer standard protocols, Milan's IRCCS-accredited facilities manage significantly higher patient volumes. This concentrated experience often leads to more robust multidisciplinary follow-up for complex immune responses.
Accessing CAR T-cell therapy in Italy is hindered by uneven geographic distribution of centers, complex regional reimbursement processes, and strict eligibility criteria. While AIFA-approved, 70% of qualified clinics are concentrated in four northern and central regions, leaving five southern regions without local access.
Bookimed Expert Insight: While standard CAR T pathways involve long waits, Milan remains the strategic choice for international and local patients. Clinics like San Raffaele combine massive clinical research with high-volume hematology departments. Their role in gene therapy trials often provides earlier access to technology than smaller regional centers.
Patient Consensus: Patients report that while public coverage exists, the 6 to 12-month wait times often necessitate early involvement of advocacy groups. Most recommend securing complete treatment documentation immediately to expedite the complex reimbursement appeals process.